Treatment of patients with high-risk myelodysplastic syndromes
暂无分享,去创建一个
[1] U. Germing,et al. Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Michael Rytting,et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.
[3] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.
[4] M. Grever,et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.
[5] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[6] E. Feldman. Farnesyltransferase inhibitors in myelodysplastic syndrome , 2006, Current Hematologic Malignancy Reports.
[7] C. Steidl,et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.
[8] J. Sierra,et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. , 2006, Haematologica.
[9] C. Steidl,et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) , 2005, Leukemia.
[10] C. Steidl,et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia , 2005, Annals of Hematology.
[11] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Lübbert,et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients , 2005, Annals of Hematology.
[13] U. Germing,et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup , 2005, Annals of Hematology.
[14] L. Rimsza,et al. Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.
[15] Y. Kanda,et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome , 2005, Leukemia.
[16] U. Germing,et al. Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies. , 2004 .
[17] G. Mufti,et al. High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM). , 2004 .
[18] U. Germing,et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.
[19] John P Klein,et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.
[20] F. Mandelli,et al. Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia. , 2004, Annals of hematology.
[21] U. Germing,et al. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome , 2003, Leukemia.
[22] G. Mufti,et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.
[23] M. Rozman,et al. Successful treatment by selective arterial embolization of severe retroperitoneal hemorrhage secondary to bone marrow biopsy in post-polycythemic myelofibrosis , 2003, Annals of Hematology.
[24] P. Greenberg,et al. Myelodysplastic syndromes. , 2013, Hematology. American Society of Hematology. Education Program.
[25] U. Germing,et al. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. , 2002, Experimental hematology.
[26] John P Klein,et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. , 2002, Blood.
[27] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] U. Germing,et al. Thalidomide for the treatment of patients with myelodysplastic syndromes , 2002, Leukemia.
[29] M. Cazzola,et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. , 2002, Haematologica.
[30] U. Germing,et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.
[31] U. Germing,et al. Long‐term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis , 2000, British journal of haematology.
[32] M. Lübbert,et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Labopin,et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.
[34] A. Ganser,et al. 174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML , 1997 .
[35] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.